Physician profile
Amar Raval
NPI 1346530755
$60,487.82
in general payments reported to CMS, 2019-2025
56 companies · $5,395 in 2025
The $5,395 reported for 2025 was more than what 91% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,323 · 2020: $2,086 · 2021: $6,637 · 2022: $23K · 2023: $9,518 · 2024: $10K · 2025: $5,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Education: $137 · Travel and Lodging: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,207.50 |
| Food and Beverage | $10,557.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Education | $137.10 |
| Travel and Lodging | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $34,065.44 | 2021-2025 | Aquabeam Robotic System, Aquabeam System |
| Medtronic, INC. | $6,120.12 | 2021-2025 | Interstim, Nuro, Altaviva |
| Coloplast Corp | $4,302.17 | 2019-2025 | Titan, Altis |
| Ethicon INC. | $2,777.50 | 2024 | |
| Axonics, INC. | $1,995.10 | 2020-2024 | Axonics, Bulkamid |
| Neotract INC. | $1,936.05 | 2019-2020 | |
| Teleflex LLC | $940.65 | 2021-2025 | Urolift, Barrigel, Solesta |
| Abbvie INC. | $807.76 | 2019-2025 | |
| Pfizer INC. | $732.05 | 2019-2025 | |
| Antares Pharma, INC. | $635.09 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Sumitomo Pharma America, INC. | $622.40 | 2023-2025 | Orgovyx, Gemtesa |
| Boston Scientific Corporation | $547.31 | 2019-2025 | Spaceoar Vue System - 10ml, General - Therapies, Ams 700 |
| Endo Pharmaceuticals INC. | $459.19 | 2019-2024 | Xiaflex, Aveed, Edex |
| Astellas Pharma US INC | $411.42 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Janssen Biotech, INC. | $388.38 | 2019-2025 | Erleada |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Raval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.